Medical Device News Magazine

GI OnDEMAND Announces Partnership with Trellus Health

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

GI OnDEMAND®, gastroenterology’s leading multidisciplinary virtual integrated care platform today announced a partnership with Trellus Health, the creator of the leading digitally delivered Inflammatory Bowel Disease (IBD) resilience driven self-management solution for all patients with IBD.

GI OnDEMAND, a joint venture between the American College of Gastroenterology and Gastro Girl, Inc., will now offer access to the Trellus scientifically validated resilience training and self-management programs, to all GI OnDEMAND and ACG members nationwide. Members will now be able to offer their patients the much-needed holistic wrap around services to help support providers and patients in between office visits wherever and whenever they need it. Trellus coordinates and delivers personalized behavioral, emotional, and nutritional support to patients with IBD via digital solutions and remote access to an expert resilience training team of coaches, dietitians, and nurse educators all while leaving the clinical care to their health care providers. The suite of Trellus programs empowers patients to live healthier and more fulfilling lives, effectively self-manage their condition, adhere to treatment plans, and engage in effective interactions with their health care team.

Marla Dubinsky, MD, CEO and Co-Founder Trellus Health said:

“Trellus represents a paradigm shift in the way that we support patients with Crohn’s disease and ulcerative colitis incorporating a whole-person methodology that has, to date, been missing from the collective approach. Trellus reflects the learnings, frustrations and passion that has resulted from the nearly 25 years both Dr Laurie Keefer and I have dedicated to improving the lives of individuals with IBD. At Trellus we hope to empower patients to master the art of self-management, manage their IBD with confidence, and improve health outcomes at a significantly lower cost.”

“GI OnDEMAND expands a provider’s ability to deliver a first in class patient self-management solution for IBD. All patients have access to a digitally delivered, resilience-based, self-management training program developed and validated at Mount Sinai (NY) to help your patients take charge of their health needs, access behavioral and emotional support in between office visits and experience better outcomes,” said William Chey, MD, FACG, of the University of Michigan and Senior Director, Nutrition and Behavioral Health Services, GI OnDEMAND. “This is exactly what our GI patients need.”

“Our partnership with Trellus Health reflects a mutual a passion for taking a multidisciplinary approach to patient care and an unwavering mission to make digestive health expertise, resources and support accessible to everyone,” said Jacqueline Gaulin, Founder, Chief Strategy Officer, Gastro Girl/GI OnDEMAND. “We look forward to working together with the Trellus team to further expand the awareness and reach of the Trellus IBD program so all patients with IBD have access to this personalized and evidence-based program that gives them the tools and the team to better manage their health and live well physically, emotionally and socially.”

Learn More About the GI OnDEMAND and Trellus Health Partnership at ACG 2022

Visit GI OnDEMAND Booth #725 at the Charlotte Convention Center during ACG’s Annual Scientific Meeting October 23-26 in Charlotte, NC

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”